Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cadonilimab + lenvatinib
- Development stage
- Phase 2
- Lead developer
- Kangfang Sainuo Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Cadonilimab + lenvatinib is a combination therapy being investigated for the treatment of hepatocellular carcinoma (HCC), specifically as a conversion therapy for unresectable cases. Cadonilimab (AK104) is a humanized, tetravalent, bispecific antibody developed by Akeso Biopharma that simultaneously targets the PD-1 and CTLA-4 immune checkpoints. By blocking these pathways, it aims to restore and enhance the anti-tumor activity of T-cells. Lenvatinib is an oral, small-molecule multi-kinase inhibitor developed by Eisai that targets vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT. The combination of dual checkpoint inhibition and anti-angiogenic therapy is intended to provide synergistic anti-tumor effects, potentially shrinking tumors to a size where surgical resection becomes feasible. This specific regimen is being evaluated in a Phase II clinical trial led by Peking Union Medical College Hospital.
- Brand names
- Kaitani
- Other names
- AK104 + lenvatinibcadonilimab plus lenvatinib
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on cadonilimab + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cadonilimab + lenvatinib.